UY38939A - Métodos de uso de composiciones de cannabinoides en aplicaciones de medicina deportiva - Google Patents

Métodos de uso de composiciones de cannabinoides en aplicaciones de medicina deportiva

Info

Publication number
UY38939A
UY38939A UY0001038939A UY38939A UY38939A UY 38939 A UY38939 A UY 38939A UY 0001038939 A UY0001038939 A UY 0001038939A UY 38939 A UY38939 A UY 38939A UY 38939 A UY38939 A UY 38939A
Authority
UY
Uruguay
Prior art keywords
methods
compositions
sports medicine
medicine applications
cannabinoid compositions
Prior art date
Application number
UY0001038939A
Other languages
English (en)
Inventor
Peyton Palaio
Original Assignee
Prec Biologics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prec Biologics filed Critical Prec Biologics
Publication of UY38939A publication Critical patent/UY38939A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan composiciones que comprenden un cannabinoide, un aceite (por ejemplo, aceite MCT o aceite de coco) y una cera, y métodos para preparar tales composiciones. Las composiciones divulgadas pueden ser útiles, por ejemplo, en el tratamiento de una lesión del músculo, articulación, cartílago y/o tendón. Este resumen está destinado a ser una herramienta de exploración con el propósito de buscar en la técnica particular y no pretende ser una limitación de la presente invención.
UY0001038939A 2019-10-30 2020-10-30 Métodos de uso de composiciones de cannabinoides en aplicaciones de medicina deportiva UY38939A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962928206P 2019-10-30 2019-10-30

Publications (1)

Publication Number Publication Date
UY38939A true UY38939A (es) 2022-04-29

Family

ID=75686693

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038939A UY38939A (es) 2019-10-30 2020-10-30 Métodos de uso de composiciones de cannabinoides en aplicaciones de medicina deportiva

Country Status (4)

Country Link
US (1) US20210128521A1 (es)
AR (1) AR120350A1 (es)
UY (1) UY38939A (es)
WO (1) WO2021086964A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11058142B1 (en) 2020-10-01 2021-07-13 Tobacco Technology, Inc. Shisha, heat-not-burn, or combustion casing with active ingredient, product and casing with active ingredient, and method of making the same
US11363834B2 (en) 2020-10-01 2022-06-21 Tobacco Technology, Inc. Shisha, heat-not-burn, or combustion casing, product, and method of making the same
CA3235080A1 (en) 2021-10-26 2023-04-05 Alexandra M CAPANO Methods of treating endometriosis and other non-cancer gynecological disorders with hemp extract
CA3235074A1 (en) 2021-10-26 2023-05-04 Alexandra M CAPANO Methods of treating ovarian cancer with hemp extract
EP4422769A2 (en) 2021-10-26 2024-09-04 Ecofibre USA Inc. Systems and methods for producing hemp extracts and compositions
US12011451B2 (en) 2022-10-26 2024-06-18 Ecofibre USA Inc. Stabilized compositions comprising cannabidiol
US12097211B2 (en) 2022-10-26 2024-09-24 Ecofibre USA Inc. Methods of treating estrogen sensitive diseases with cannabis extract

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
US10052339B2 (en) * 2014-03-21 2018-08-21 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
US20160338974A1 (en) * 2015-03-02 2016-11-24 Afgin Pharma, Llc Topical regional neuro affective therapy with cannabinoid combination products
ES2977485T3 (es) * 2018-03-14 2024-08-26 Poviva Corp Administración transdérmica y/o dérmica de agentes activos lipofílicos
WO2019186544A1 (en) * 2018-03-26 2019-10-03 Raphael Luxenbourg Topical cannabidiol compositions and methods for protecting the skin from ultra-violet radiation

Also Published As

Publication number Publication date
WO2021086964A1 (en) 2021-05-06
US20210128521A1 (en) 2021-05-06
AR120350A1 (es) 2022-02-09

Similar Documents

Publication Publication Date Title
UY38939A (es) Métodos de uso de composiciones de cannabinoides en aplicaciones de medicina deportiva
SV2017005471A (es) Derivados de quinazolina utilizados para tratar el vih
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2020005887A2 (es) Compuestos policíclicos como inhibidores alostéricos de shp2
CL2020002841A1 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
UY38237A (es) Derivados sustituidos de la carboxamida dihidropirazolo pirazina
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
BR112017012184A2 (pt) composições e métodos para reticular polímeros na presença de oxigênio atmosférico
BR112018073711A2 (pt) dispositivo de distração osteogênica telescópico intracorporal, dispositivo de produção de força extracorporal, método de alongamento de osso e disposição de alongamento de osso
AR101656A1 (es) Materiales biofotónicos a base de silicona y usos de los mismos
CO2023013397A2 (es) Compuestos de tienopirrol
CL2020001349A1 (es) Compuestos, composición y uso de los mismos como moduladores de la expresión de pcsk9. (divisional solicitud 201902574)
PE20181203A1 (es) Derivados de fenilo como agonistas de receptor de cannabinoides 2
BR112019003169A2 (pt) polietilenos modificados
CL2020000334A1 (es) Formas cristalinas de 2-[(2,4-diclorofenil)metil]-4,4-dimetil-isoxazolidin-3-ona.
CO2021000884A2 (es) Composiciones de esterquat
CL2021001044A1 (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria
AR112466A1 (es) Complejo cosmético para la hidratación bioactiva, composición cosmética, uso y método
BR112017015999A2 (pt) composição espumável, espuma, e, método para preparar a mesma.
CL2019002840A1 (es) Formas cristalinas de (s)-afoxolaner.
CO2021001174A2 (es) Inhibidores de ckd8/19
CL2020002959A1 (es) Tratamiento de enfermedades asociadas con el envejecimiento con moduladores de la leucotrieno a4 hidrolasa.
CL2019002020A1 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer.
CO2022013603A2 (es) Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20240815